Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells (Q39369159)

11 September 2017

title

Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells (English)

1 reference

11 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

Ying-Ray Lee

9

0 references

Tien-Chun Chang

object named as

Tien-Chun Chang

2

0 references

Yi-Wen Liu

5

object named as

Yi-Wen Liu

1 reference

11 September 2017

Shih-Che Hua

1

1 reference

11 September 2017

Hau-Ren Chen

3

1 reference

11 September 2017

Chieh-Hsiang Lu

4

1 reference

11 September 2017

Shu-Hsin Chen

6

1 reference

11 September 2017

Hui-I Yu

7

1 reference

11 September 2017

Yi-Ping Chang

8

1 reference

11 September 2017

language of work or name

1 reference

4 April 2012

1 reference

11 September 2017

published in

Pharmaceutical Research

1 reference

11 September 2017

volume

29

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

1990-2005

1 reference

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Dedifferentiation of lineage-committed cells by a small molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Reversine stimulates adipocyte differentiation and downregulates Akt and p70(s6k) signaling pathways in 3T3-L1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Reversine-treated fibroblasts acquire myogenic competence in vitro and in regenerating skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Reversine enhances generation of progenitor-like cells by dedifferentiation of annulus fibrosus cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Novel chemically defined approach to produce multipotent cells from terminally differentiated tissue syncytia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Overexpression of thyroid hormone receptor beta1 is associated with thyrotropin receptor gene expression and proliferation in a human thyroid carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Cell-cycle dysregulation and anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

The cellular geography of aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Chromosomal passengers: the four-dimensional regulation of mitotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0727-3

Centrosome cohesion is regulated by a balance of kinase and phosphatase activities

21 January 2018

1 reference

12 December 2020

The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells

1 reference

12 December 2020

Management guidelines for patients with thyroid nodules and differentiated thyroid cancer

1 reference

12 December 2020

Mitotic kinase expression and colorectal cancer progression

1 reference

12 December 2020

Identification of a functional destruction box in the Xenopus laevis aurora-A kinase pEg2

1 reference

12 December 2020

10.1007/S11095-012-0727-3

Identifiers

DOI

1 reference

11 September 2017

1 reference